Cargando…

Comparison of Choroidal Thickness, Foveal Avascular Zone, and Macular Capillary Density in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Ranibizumab or Aflibercept—A Prospective Study

This prospective comparative case series aims to compare best-corrected visual acuity (BCVA), retinal microvasculature, and retinal structural changes in patients treated with either ranibizumab or aflibercept for macular edema (ME) secondary to treatment-naïve branch retinal vein occlusion (BRVO) b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yu-Te, Wang, I, Lin, Chun-Ju, Lai, Chun-Ting, Hsia, Ning-Yi, Chen, Huan-Sheng, Tien, Peng-Tai, Bair, Henry, Lin, Jane-Ming, Chen, Wen-Lu, Chen, Chang-He, Wu, Wen-Chuan, Tsai, Yi-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031043/ https://www.ncbi.nlm.nih.gov/pubmed/35454378 http://dx.doi.org/10.3390/medicina58040540

Ejemplares similares

Changes of Estimated Glomerular Filtration Rate and Glycated Hemoglobin A1c in Diabetic Macular Edema Patients Treated by Ranibizumab and Aflibercept in the Tertiary Referral Hospital
por: Ku, Wei-Ning, et al.
Publicado: (2022)

Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema
por: Sarda, Valérie, et al.
Publicado: (2020)

Intravitreal aflibercept combined with transpupillary thermotherapy in the treatment of refractory macular edema due to primary uveal melanoma
por: Huang, Yu-Te, et al.
Publicado: (2022)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease
por: Hsia, Ning-Yi, et al.
Publicado: (2021)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Short-Term Outcomes of Refractory Diabetic Macular Edema Switch From Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience
por: Hsia, Ning-Yi, et al.
Publicado: (2021)

Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections
por: Chang, Yen-Chieh, et al.
Publicado: (2023)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema
por: Mori, Yuki, et al.
Publicado: (2016)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
por: Herbaut, Antoine, et al.
Publicado: (2017)

Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice
por: Plaza-Ramos, Pablo, et al.
Publicado: (2019)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection
por: Nawar, Amin E., et al.
Publicado: (2022)

Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema
por: Lin, Tai-Chi, et al.
Publicado: (2021)

Temporal and double inverted internal limiting membrane flap for bilateral choroidal ruptures complicated by bilateral macular holes
por: Huang, Li-Ying, et al.
Publicado: (2022)

Clinical Relevance of Parafoveal Intercapillary Spaces and Foveal Avascular Zone in Diabetic Retinopathy Without Macular Edema
por: Terada, Noriko, et al.
Publicado: (2022)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
por: Alsaedi, Nasser G, et al.
Publicado: (2021)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Change in the Foveal Avascular Zone and Macular Capillary Network Density after Hyperbaric Oxygen Therapy in Healthy Retina
por: Çevik, Sadık Görkem, et al.
Publicado: (2021)

Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema After Dexamethasone Implants
por: Huang, Yu-Te, et al.
Publicado: (2022)

Foveal eversion patterns in diabetic macular edema
por: Arrigo, Alessandro, et al.
Publicado: (2022)

Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab
por: Ebneter, Andreas, et al.
Publicado: (2016)

Age, Initial Central Retinal Thickness, and OCT Biomarkers Have an Influence on the Outcome of Diabetic Macular Edema Treated With Ranibizumab– Tri-center 12-Month Treat-and-Extend Study
por: Lai, Chun-Ting, et al.
Publicado: (2021)

Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
por: Rishi, Pukhraj, et al.
Publicado: (2011)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
por: Kucukevcilioglu, Murat, et al.
Publicado: (2023)

The role of aflibercept in the management of diabetic macular edema
por: Chang, Andrew A, et al.
Publicado: (2015)

The clinical utility of aflibercept for diabetic macular edema
por: Stewart, Michael W
Publicado: (2015)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Jin, Ki Won, et al.
Publicado: (2021)

Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
por: Gascon, Pierre, et al.
Publicado: (2021)

Three year outcomes of intravitreal ranibizumab and aflibercept treatment of patients with diabetic macular edema: A comparative study
por: Akbas, Yusuf Berk, et al.
Publicado: (2023)

Foveal Microvascular Integrity Association With Anti-VEGF Treatment Response for Diabetic Macular Edema
por: Huang, Wei-Hsuan, et al.
Publicado: (2021)

Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
por: Moradian, Siamak, et al.
Publicado: (2023)

A Novel Machine Learning Algorithm to Automatically Predict Visual Outcomes in Intravitreal Ranibizumab-Treated Patients with Diabetic Macular Edema
por: Chen, Shao-Chun, et al.
Publicado: (2018)

Visualization of changes in the foveal avascular zone in both observed and treated diabetic macular edema using optical coherence tomography angiography
por: Gill, Aditya, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p7tafcpqr7bnl3vrh0ccr50jsa